EMA starts evaluating use of COVID-19 vaccine Comirnaty in children aged 5 to 11
Comirnaty is a vaccine for preventing COVID-19, currently authorised for use in people aged 12 and older.
It contains a molecule called messenger RNA (mRNA) with instructions for producing a protein, known as the spike protein, which is naturally present in SARS-CoV-2, the virus that causes COVID-19.
The vaccine works by preparing the body to defend itself against SARS-CoV-2. EMA’s human medicines committee (CHMP) will review the data on the vaccine, including results from an ongoing clinical study involving children aged 5 to 11, in order to decide whether to recommend extending its use.
The CHMP’s opinion will then be forwarded to the European Commission, which will issue a final decision. ■